#124841
#124842
Re: Farmas USA
#124843
Re: Farmas USA
Yo las mantengo. La idea es surfear la ola hasta que empiecen resultados y salir antes. Del último informe de resultados:
Program Update
Program Update
- Etrasimod atopic dermatitis (AD) ADVISE Phase 2b trial enrollment completed; topline data expected Q4 2020
- Etrasimod ELEVATE UC 52 Phase 3 trial in ulcerative colitis (UC) ongoing and on track; ELEVATE UC 12 Phase 3 trial expected to initiate in H2 2020; topline data for both trials expected by year end 2021
- Etrasimod CULTIVATE Phase 2b dose-ranging trial in Crohn's disease (CD) initiated and ongoing; confirming plans to help facilitate availability of topline data in 2021; continue to suspend overall program guidance based on expected COVID-19 impact
- Etrasimod eosinophilic esophagitis (EoE) Phase 2b and alopecia areata (AA) Phase 2 planning ongoing; initiation in 2020 dependent on COVID-19 situation in Q3/4
- Olorinab CAPTIVATE Phase 2b trial in abdominal pain associated with irritable bowel syndrome (IBS-C, IBS-D) ongoing; experiencing some COVID-19 related impact on trial enrollment; topline data expected Q1 2021
- APD418 in acute heart failure (AHF) with Fast Track designation; Phase 1 trial has resumed; topline data expected Q4 2020
Por lo que lo primero sería:
- Etrasimod atopic dermatitis (AD) ADVISE Phase 2b Q4 2020
- APD418 in (AHF) Phase 1 Q4 2020
Q4 acaba de empezar por lo que espero que no tengan mucha prisa.
ARNA
ARNA
#124844
Re: Farmas USA
#124845
Re: Farmas USA
#124846
Re: Farmas USA
#124847
Re: Farmas USA
#124848